Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;